EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Impact of immunochemotherapy with R‐bendamustine or R‐CHOP for treatment naïve advanced‐stage follicular lymphoma: A subset analysis of the FOLL12 trial by Fondazione Italiana Linfomi

Maria E Nizzoli, Martina Manni iD, Chiara Ghiggi, Alessandro Pulsoni iD, Gerardo Musuraca, Michele Merli iD, Catello Califano, Alessia Bari, Massimo Massaia, Annarita Conconi iD, Pellegrino Musto, Donato Mannina und 17 weitere

Hematological Oncology · 2023

DOI: 10.1002/hon.3184 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Hematological Oncology, 2023. Verfasst von Maria E Nizzoli und 28 weiteren Autor:innen. Beteiligte Einrichtung: Hematology Unit, Azienda Unitа Sanitaria Locale-IRCCS di Reggio Emilia, Reggio Emilia, Italy. Hauptthemen laut MEDLINE: Lymphoma, Follicular. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministero della Salute, Associazione Angela Serra per la Ricerca sul Cancro, Società Italiana di Ematologia.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We conducted a post hoc analysis of the FOLL12 trial to determine the impact of different initial immunochemotherapy (ICT) regimens on patient outcomes. Patients were selected from the FOLL12 trial, which included adults with stage II–IV follicular lymphoma (FL) grade 1–3a and high tumor burden. Patients were randomized 1:1 to receive either standard ICT followed by rituximab maintenance (RM) or the same ICT followed by a response‐adapted approach. ICT consisted of rituximab‐bendamustine (RB) or rituximab, cyclophosphamide, doxorubicin, and prednisone (R‐CHOP), per physician's decision. A total of 786 patients were included in this analysis, 341 of whom received RB and 445 R‐CHOP. RB was more frequently prescribed to older subjects, females, patients without bulky disease, and those with grade 1–2 FL. After a median of 56 months of follow‐up, R‐CHOP and RB had similar progression‐free survival (PFS) (Hazard Ratio for RB 1.11, 95% CI 0.87–1.42, p = 0.392). Standard RM was associated with improved PFS compared to response‐adapted management both after R‐CHOP and RB. Grade 3–4 hematologic adverse events were more frequent with R‐CHOP during induction treatment and more frequent with RB during RM. Grade 3–4 infections were more frequent with RB. RB was also associated with a higher incidence of transformed FL. R‐CHOP and RB showed similar activity and efficacy, but with different safety profiles and long‐term events, suggesting that the treating physician should carefully select the most appropriate chemotherapy regimen for each patient based on patient's individual characteristics, choices, and risk profile.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, FollicularAdultFemaleHumansRituximabBendamustine HydrochloridePrednisoneNeoplasm Recurrence, LocalVincristineCyclophosphamideDoxorubicinAntineoplastic Combined Chemotherapy Protocols

Stichwörter der Autor:innen

follicular lymphomaimmunochemotherapysurvival

Substanzen

RituximabBendamustine HydrochloridePrednisoneVincristineCyclophosphamideDoxorubicin

Autor:innen und Institutionen

  • Hematology Unit, Azienda Unitа Sanitaria Locale-IRCCS di Reggio Emilia, Reggio Emilia, Italy.
  • Clinical and Experimental Medicine PhD Program, University of Modena and Reggio Emilia, Modena, Italy.
  • Surgical, Medical and Dental Department of Morphological Sciences Related to Transplant, Oncology and Regenerative Medicine, University of Modena and Reggio Emilia, Modena, Italy.
  • Department of Surgical Sciences and Integrated Diagnostics (DISC), University of Genoa, Genoa, Italy.
  • Department of Translational and Precision Medicine, Sapienza University - UOC Ematologia, S.M. Goretti Hospital, Latina, Italy.
  • IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy.

ORCID-Profile: Martina Manni, Alessandro Pulsoni, Michele Merli, Annarita Conconi

Förderung

  • Ministero della Salute
  • Associazione Angela Serra per la Ricerca sul Cancro
  • Società Italiana di Ematologia

Zitieren

APA

Nizzoli, M. E., Manni, M., Ghiggi, C., Pulsoni, A., Musuraca, G., Merli, M., Califano, C., Bari, A., Massaia, M., Conconi, A., Musto, P., Mannina, D., Perrone, T., Re, F., Galimberti, S., Gini, G., Capponi, M., Vitolo, U., Usai, S. V., …, & Luminari, S. (2023). Impact of immunochemotherapy with R‐bendamustine or R‐CHOP for treatment naïve advanced‐stage follicular lymphoma: A subset analysis of the FOLL12 trial by Fondazione Italiana Linfomi. Hematological Oncology. https://doi.org/10.1002/hon.3184

Vancouver

Nizzoli ME, Manni M, Ghiggi C, Pulsoni A, Musuraca G, Merli M, et al. Impact of immunochemotherapy with R‐bendamustine or R‐CHOP for treatment naïve advanced‐stage follicular lymphoma: A subset analysis of the FOLL12 trial by Fondazione Italiana Linfomi. Hematological Oncology. 2023. doi:10.1002/hon.3184

BibTeX
@article{Nizzoli2023,
  author = {Nizzoli, Maria E and Manni, Martina and Ghiggi, Chiara and Pulsoni, Alessandro and Musuraca, Gerardo and Merli, Michele and Califano, Catello and Bari, Alessia and Massaia, Massimo and Conconi, Annarita and Musto, Pellegrino and Mannina, Donato and Perrone, Tommasina and Re, Francesca and Galimberti, Sara and Gini, Guido and Capponi, Monia and Vitolo, Umberto and Usai, Sara V and Stefani, Piero M and Ballerini, Filippo and Liberati, Anna M and Pennese, Elsa and Pastore, Domenico and Skrypets, Tetiana and Catellani, Hillary and Marcheselli, Luigi and Federico, Massimo and Luminari, Stefano},
  title = {Impact of immunochemotherapy with R‐bendamustine or R‐CHOP for treatment naïve advanced‐stage follicular lymphoma: A subset analysis of the FOLL12 trial by Fondazione Italiana Linfomi},
  journal = {Hematological Oncology},
  year = {2023},
  doi = {10.1002/hon.3184}
}
Kostenlos starten →